Clinical Trial Update: A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel [Phase 2]

View source ↗

Summary

Ongoing Phase 2 clinical trial evaluating ciltacabtagene autoleucel (Carvykti) for multiple myeloma; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Carvykti (ciltacabtagene autoleucel)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Multiple Myeloma | Phase 2 | Status: RECRUITING